Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe

cancer treatment

  • Home
  • cancer treatment
Quality, Cost, and Timeliness of Cancer Treatment in Medicare Advantage Versus Traditional Medicare: An Evidence-Based Review
Posted inClinical Updates news Oncology Public Health

Quality, Cost, and Timeliness of Cancer Treatment in Medicare Advantage Versus Traditional Medicare: An Evidence-Based Review

Posted by MedXY By MedXY 07/17/2026
Medicare Advantage beneficiaries with cancer receive guideline-concordant treatment similarly to Traditional Medicare enrollees but at lower costs and comparable timeliness, highlighting implications for healthcare policy and cost-effective oncology care delivery.
Read More
Sustained Locoregional Control With Deintensified Chemoradiotherapy for HPV Oropharyngeal Carcinoma
Posted innews Oncology Otorhinolaryngology

Sustained Locoregional Control With Deintensified Chemoradiotherapy for HPV Oropharyngeal Carcinoma

Posted by MedXY By MedXY 05/08/2026
A cohort study demonstrates that reduced-dose 60-Gy chemoradiotherapy effectively maintains locoregional control in HPV-positive oropharyngeal cancer patients while minimizing treatment toxicity, with 5-year survival rates exceeding 92%.
Read More
RNA Cancer Vaccines: Revolutionary Advances Bringing Hope for 2029 Clinical Use
Posted inHematology-Oncology news Oncology

RNA Cancer Vaccines: Revolutionary Advances Bringing Hope for 2029 Clinical Use

Posted by MedXY By MedXY 11/14/2025
RNA cancer vaccines are emerging as powerful tools against hard-to-treat cancers, with breakthroughs in melanoma, pancreatic, and brain cancers showing promise for widespread clinical adoption by 2029.
Read More
From Discovery to Breakthroughs: How Multiple Myeloma Survival Has Doubled in 20 Years
Posted inHematology-Oncology

From Discovery to Breakthroughs: How Multiple Myeloma Survival Has Doubled in 20 Years

Posted by MedXY By MedXY 10/24/2025
Over the past two decades, advances in therapy have doubled the median survival of multiple myeloma patients, transforming this once devastating cancer into a more manageable disease through targeted drugs and immune therapies.
Read More
Cancer Treatment and Genetic Predisposition Drive Subsequent Neoplasm Risk in Childhood Cancer Survivors
Posted inClinical Updates news Oncology Specialties

Cancer Treatment and Genetic Predisposition Drive Subsequent Neoplasm Risk in Childhood Cancer Survivors

Posted by MedXY By MedXY 08/03/2025
A comprehensive analysis reveals that radiotherapy, chemotherapy, and genetic factors substantially contribute to subsequent neoplasms in long-term childhood cancer survivors, while lifestyle factors play a minimal role.
Read More
AI-Designed Proteins Revolutionize Personalized Cancer Treatment
Posted inMedical News Oncology

AI-Designed Proteins Revolutionize Personalized Cancer Treatment

Posted by MedXY By MedXY 07/25/2025
AI-powered protein design offers a fast, personalized approach to cancer treatment, enhancing immune response and minimizing side effects.
Read More
  • Secondary Autoimmune and Inflammatory Diseases Post-Allogeneic Hematopoietic Stem Cell Transplantation: Incidence, Risk Factors, and Clinical Outcomes from the EBMT Registry
  • Cytogenetic Insights into Multiple Myeloma Outcomes Despite MRD Negativity Post-Autologous Stem Cell Transplant
  • CD19 CAR T-cell Therapy Without Lymphodepletion Shows Promise in Pemphigus Vulgaris: Insights from the RESET-PV Trial
  • Prognostic Impact of Single Moderate Exacerbation in COPD Patients: Insights from 12-Year Mortality and Future Exacerbation Risk Analysis
  • Acute Exacerbation in Fibrotic Interstitial Lung Disease: Key Recommendations from the 2026 International Working Group Report
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号

  • English
  • 日本語
  • Tiếng Việt
  • 中文

Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular risk chronic kidney disease clinical trial clinical trials critical care diabetes epidemiology health heart failure hepatocellular carcinoma Hypertension immunotherapy inflammation MASLD mental health metformin Mortality myocardial infarction nutrition obesity older adults oncology Pediatrics precision medicine Pregnancy prostate cancer public health quality of life randomized clinical trial randomized controlled trial randomized trial risk stratification SGLT2 inhibitors stroke type 1 diabetes type 2 diabetes weight loss women's health

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top
Sign in